Gina Mazzariello - Amylyx Pharmaceuticals Chief Counsel
| AMLX Etf | USD 3.65 0.08 2.14% |
| Age | 53 |
| Address | 43 Thorndike Street, Cambridge, MA, United States, 02141 |
| Phone | 617 682 0917 |
| Web | https://amylyx.com |
Latest Insider Transactions
Gina Mazzariello Latest Insider Activity
Tracking and analyzing the buying and selling activities of Gina Mazzariello against Amylyx Pharmaceuticals etf is an integral part of due diligence when investing in Amylyx Pharmaceuticals. Gina Mazzariello insider activity provides valuable insight into whether Amylyx Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Amylyx Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amylyx Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Gina Mazzariello over three months ago Disposition of 8709 shares by Gina Mazzariello of Amylyx Pharmaceuticals at 3.1967 subject to Rule 16b-3 | ||
Gina Mazzariello over six months ago Disposition of 10455 shares by Gina Mazzariello of Amylyx Pharmaceuticals at 1.8799 subject to Rule 16b-3 |
Amylyx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5131) % which means that it has lost $0.5131 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0088) %, meaning that it created substantial loss on money invested by shareholders. Amylyx Pharmaceuticals' management efficiency ratios could be used to measure how well Amylyx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
| Showing other executives | One Year Return | ||
| Russell MS | Acumen Pharmaceuticals | 67 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Christine CPA | Mereo BioPharma Group | 44 | |
| Jackie Parkin | Mereo BioPharma Group | 67 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Alexandra HughesWilson | Mereo BioPharma Group | 54 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Keith MD | X4 Pharmaceuticals | 54 | |
| MS MBA | Inozyme Pharma | 48 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| MA MS | Inozyme Pharma | N/A | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.51 |
Amylyx Pharmaceuticals Money Managers
| Debra Canner, Global CHRO | ||
| Margaret MBA, Global Officer | ||
| Shauna Horvath, Head Marketing | ||
| Gina JD, Chief Counsel | ||
| Chris Aiello, Head GM | ||
| Machelle Manuel, VP Affairs | ||
| Justin Klee, CoCEO CoFounder | ||
| Camille MD, Chief Officer | ||
| James MBA, Chief Officer | ||
| MD MBA, Global Officer | ||
| Tammy Sarnelli, Global Affairs | ||
| Joshua Cohen, CoCEO CoFounder | ||
| Tom Holmes, Chief Officer | ||
| Gina Mazzariello, Chief Counsel | ||
| Keith White, Head Access | ||
| Lindsey Allen, Head Communications | ||
| Linda Arsenault, Chief Officer |
Amylyx Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Amylyx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | 61.13 % | ||||
| Current Valuation | 148.88 M | ||||
| Shares Outstanding | 88.6 M | ||||
| Shares Owned By Insiders | 11.69 % | ||||
| Shares Owned By Institutions | 65.72 % | ||||
| Number Of Shares Shorted | 3.38 M | ||||
| Price To Book | 1.96 X | ||||
| Price To Sales | 3.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.